Virus filtration process design and implementation

Process Scale Bioseparations for the Biopharmaceutical Industry

Volumn , Issue , 2006, Pages 333-365

  Phillips, Michael W ^a   Bolton, Glen ^b   Krishnan, Mani ^a   Lewnard, John J ^a   Raghunath, Bala ^a  

^a MILLIPORE CORPORATION   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67149104928     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (21)

1. FDA. Draft points to consider (PTC) in the manufacture and testing of monoclonal antibody products for human use. CBER 1994.
2. PDA. PDA Technical Report No. 41 Virus Filtration 2005.
3. Levy RV, Phillips MW, and Lutz H. Filtration and the removal of viruses from biopharmaceuticals. In Meltzer TH and Jornitz MW, Eds. Filtration in the Biopharmaceutical Industry. New York: Marcel Dekker, 1998, pp. 619-646.
4. Perry RH and Green DW. Perry's Chemical Engineers' Handbook, 6th ed. New York: McGraw-Hill, 1984.
5. Grace HP. Structure and performance of filter media. AIChE J. 1956. 2:307.
6. Hermia J. Constant pressure blocking filtration laws-application to power-law non-newtonian fluids. Trans. IchemE 1982; 60:183-187.
7. Hermans PH and Bredee HL. Principles of the mathematical treatment of constant-pressure filtration. J. Soc. Chem. Ind. 1936; 55T:1-4.
8. Badmington F, Wilkins R, Payne M, and Honig ES. Vmax testing for practical microfiltration train scale-up in biopharmaceutical processing. Biopharm 1995; 8(7):46-52.
9. Bolton G, LaCasse D, and Kuriyel R. Combined models of membrane fouling: development and application to microfiltration and ultrafiltration of biological fluids. J. Memb. Sci. in press.
10. Ho C and Zydney AL. A combined pore blockage and cake filtration model for protein fouling during microfiltration. J. Coll. Inter. Sci. 2000; 232:389-399.
11. Ireland T, Lutz H, Siwak M, and Bolton G. Viral filtration of plasma-derived human IgG. Biopharm. Int. 2004; 17:38-44.
12. Siwak M. Process for prefiltration of a protein solution. U.S. Patent US20030201229 A1, 2003.
13. Lutz H. Membrane filtration with optimized addition of second liquid to maximize flux. U.S. Patent 5,597,486. 1997.
14. CPMP EMEA. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses 1996. CPMP/BWP/268/95.
15. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, and Xu Y. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol. Bioeng. 2003; 82:321-329.
16. Bolton G, Cabatingan M, Rubino M, Lute S, Brorson K, and Bailey M. Normal flow virus filtration: detection and assessment of the endpoint in bioprocessing. Biotechnol. Appl. Biochem. 2005; 42:133-142.
17. Previsani N, Fontana S, Hirt B, and Beard P. Growth of the parvovirus minute virus of mice MVMp3 in EL4 lymphocytes is restricted after cell entry and before viral DNA amplification: cell-specific differences in virus uncoating in vitro. J. Virol. 1997; 71:7769-7780.
18. Hirasaki T, Noda T, Nakano H, Ishizaki T, Manabe S, and Yamamoto N. Mechanisms of removing Japanese Encephalitis Virus (JEV) and gold particles using cuprammonium regenerated cellulose hollow fiber (i-BMM or BMM) from aqueous solution containing protein. Polym. J. 1994; 26:1244-1256.
19. Omar A and Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002; 42:1005-1010.
20. Carter J and Lutz H. An overview of viral filtration in biopharmaceutical manufacturing. Eur. J. Parenter. Sci. 2002; 7:72-78.
21. Phillips MW. Integrity testing virus-retentive membranes. Proceedings from the PDAFourth International Congress. Vienna, Austria, 1996.